IP Library › Granted Patent US 12,478,681
Granted Patent B2
US 12,478,681 · App. 18/187,224 · Granted Nov 25, 2025

Non-activated, amorphous, pH neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals

Inventor: Darlene E. McCord (Chattanooga, TN)
Assignee: Darlene E. McCord
A61K47/46A61K9/0014A61K9/06A61K31/05A61K31/7048A61K35/02A61K47/10A61K47/34A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,478,681
App. No.
18/187,224
Granted
Nov 25, 2025
Kind
B2
Abstract

Clay delivery systems for providing antimicrobial compositions are provided. The delivery systems include a two-part active excipient system that delivers clay for various applications of use, including topical applications. The two-part delivery system can include a first part comprising suspending agent(s), poloxamer and optionally a gellant, and a second part that is simultaneously delivered therewith comprising one or more nonionic EO-PO block copolymers in a water-based system. The delivery systems beneficially provide clays in a stable system that also unexpectedly accelerate the release of the clay into the water system for activation and delivery that is enhanced by the poloxamers into the tissue or organ of the body in need of treatment thereof.

Claims (28)

1 . A delivery system for clay comprising:

a housing containing a two-part active excipient system comprising a first part and a second part;

wherein the first part comprises clay, a suspending agent, at least two nonionic block EO-PO copolymers, and optionally a gellant; and

wherein the second part comprises at least one nonionic block EO-PO copolymer in a pH neutral water-based system, and

wherein the ratio of the first part to the second part is from about 1:1 to about 9:1.

2 . The delivery system of claim 1 , wherein the housing is a dual chamber dispensing device comprising a dual chamber tube, sachet or syringe.

3 . The delivery system of claim 1 , wherein the suspending agent(s) is present in the amount of about 20-80 wt-% of the delivery system, wherein the at least two nonionic block EO-PO copolymers in the first part are present in the amount of about 3 wt-% to about 25 wt-% of the delivery system, and wherein the at least one nonionic block EO-PO copolymer in the second part is present in the amount of about 3 wt-% to about 35 wt-% of the delivery system.

4 . The delivery system of claim 1 , wherein the suspending agent is propylene glycol, polyethylene glycol or propanediol.

5 . The delivery system of claim 1 , wherein the at least two nonionic block EO-PO copolymer in the first part and the at least one nonionic block EO-PO copolymer in the second part comprises poly (ethylene oxide) (PEO) and poly (propylene oxide) (PPO).

6 . The delivery system of claim 1 , wherein the at least two nonionic block EO-PO copolymer in the first part have the formula PEO a -PPO b -PEO a , where the sum of a=70-120 and b=40-65.

7 . The delivery system of claim 1 , wherein the at least one nonionic block EO PO copolymer in the second part has the formula PEO a -PPO b -PEO a , where the sum of a=70-120 and b=40-65 and/or where the sum of a=70-100 and b=20-35.

8 . The delivery system of claim 1 , wherein the gellant comprises a polysaccharide or gum, and is present in the amount from about 0.1-20 wt-% of the delivery system.

9 . The delivery system of claim 1 , wherein the average particle size of the clay is between about 10-100 microns, 10-50 microns, or 10-25 microns in diameter.

10 . The delivery system of claim 1 , wherein the clay is a natural clay or clay mineral, a synthetic clay or clay mineral, or combinations thereof, and wherein the clay is sterilized.

11 . A method for using a clay delivery system for antimicrobial treatment comprising:

combining parts of a two-part active excipient clay composition, wherein the first part comprises sterilized clay, suspending agent(s), at least two nonionic block EO-PO copolymers, and optionally a gellant, and wherein the second part comprises at least one nonionic block EO-PO copolymer in a pH neutral water-based system, and wherein the ratio of the first part to the second part in the composition is from about 1:1 to about 9:1;

accelerating the release of the clay into the water-based system;

activating the clay; and

delivering the clay composition to a tissue or organ of the body.

12 . The method of claim 11 , wherein the clay is activated upon contact of the water to the water-based system.

13 . The method of claim 11 , wherein the tissue or organ is skin, mucosal cells, tissues, a wound, intestinal track, ear canal, nasal passages, oral cavities or a combination thereof.

14 . The method of claim 11 , wherein the at least one nonionic block EO-PO copolymer in the second part enhances the delivery of the clay composition to the surface, and wherein the at least two nonionic block EO-PO copolymers in the first part are poloxamer 407 and/or poloxamer 188, and the at least one nonionic block EO-PO copolymer in the second part is poloxamer 407, poloxamer 85, poloxamer 105 and/or poloxamer 188.

15 . The method of claim 11 , wherein the clay composition is topically applied to the tissue or organ, and wherein the clay composition removes oils, secretions, toxins, and contaminants from the surface.

16 . The method of claim 11 , wherein the clay composition further comprises a therapeutic agent.

17 . The method of claim 11 , wherein after the activating of the clay, the antimicrobial activity of the clay lasts for a period of at least about 12 hours, at least about 24 hours, or at least about 48 hours, and wherein the clay composition is dosed at least one to four times per day, and/or for a few days to a few months.

18 . The method of claim 11 , wherein the clay composition is administered in combination with an antibiotic or additional therapeutic agent.

19 . The method of claim 18 , wherein the clay composition results in at least a 50% reduction in antibiotic usage for a course of treatment, and/or wherein the tissue or organ of the body is in need of treatment for a bacterial pathogen.

20 . The method of claim 19 , wherein the bacterial pathogen is gastrointestinal bacteria comprising C. diff . and/or wherein the clay composition provides a 99.99% log reduction of microbial populations on the tissue or organ of the body.

Continuity (3)
Continuation 16947698 · Aug 13, 2020
Provisional Application 62885986 · Aug 13, 2019
Related Publication 20230226108A1 · Jul 20, 2023
References Cited (159)
US 3449492A · Jensen · 1969 [cited by applicant]
US 4946829A · Seubert et al. · 1990 [cited by applicant]
US 5470581A · Grillo et al. · 1995 [cited by applicant]
US 5744151A · Capelli · 1998 [cited by applicant]
US 5935889A · Murrell et al. · 1999 [cited by applicant]
US 6042839A · Lahanas et al. · 2000 [cited by applicant]
US 6399092B1 · Hobson et al. · 2002 [cited by applicant]
US 6420473B1 · Chittamuru et al. · 2002 [cited by applicant]
US 9095542B2 · Zheng et al. · 2015 [cited by applicant]
US 9675077B2 · Parsons · 2017 [cited by applicant]
US 9707180B2 · Sackler · 2017 [cited by applicant]
US 9993421B2 · McPherson et al. · 2018 [cited by applicant]
US 10046079B2 · Mukhopadhyay et al. · 2018 [cited by applicant]
US 10105388B2 · Kaestner · 2018 [cited by applicant]
US 11090366B2 · LoVetri et al. · 2021 [cited by applicant]
US 11103433B2 · Gawande et al. · 2021 [cited by applicant]
US 11124897B1 · Abudula et al. · 2021 [cited by applicant]
US 20040157766A1 · Embil et al. · 2004 [cited by applicant]
US 20050019390A1 · Kohnke · 2005 [cited by applicant]
US 20050207997A1 · Dixit · 2005 [cited by examiner]
US 20080026079A1 · Carpenter et al. · 2008 [cited by applicant]
US 20080254112A1 · Klokkers et al. · 2008 [cited by applicant]
US 20090017078A1 · Buderer et al. · 2009 [cited by applicant]
US 20100130910A1 · Berenson · 2010 [cited by applicant]
US 20100137249A1 · Wang et al. · 2010 [cited by applicant]
US 20100173003A1 · SenGupta · 2010 [cited by examiner]
US 20100256369A1 · Suga et al. · 2010 [cited by applicant]
US 20100291093A1 · Janda et al. · 2010 [cited by applicant]
US 20120219497A1 · Wellisz et al. · 2012 [cited by applicant]
US 20130004544A1 · Metge et al. · 2013 [cited by applicant]
US 20130317094A1 · Mathee et al. · 2013 [cited by applicant]
US 20160101129A1 · Kaestner · 2016 [cited by applicant]
US 20160200634A1 · Zaseybida et al. · 2016 [cited by applicant]
US 20160263007A1 · Strand · 2016 [cited by examiner]
US 20170251674A1 · Naik et al. · 2017 [cited by applicant]
US 20180021374A1 · Tuba · 2018 [cited by applicant]
US 20180125808A1 · Ala'Aldeen et al. · 2018 [cited by applicant]
US 20190054185A1 · Abduljauwad et al. · 2019 [cited by applicant]
US 20190256431A1 · Zaseybida et al. · 2019 [cited by applicant]
US 20200276458A1 · Daniels · 2020 [cited by applicant]
US 20210046186A1 · McCord · 2021 [cited by applicant]
US 20210106717A1 · Gittard et al. · 2021 [cited by applicant]
US 20210121575A1 · Salamone et al. · 2021 [cited by applicant]
US 20210253804A1 · Spina et al. · 2021 [cited by applicant]
US 20220040066A1 · Appavoo et al. · 2022 [cited by applicant]
US 20220298208A1 · West et al. · 2022 [cited by applicant]
US 20220313571A1 · Hu et al. · 2022 [cited by applicant]
US 20230131873A1 · Mccord et al. · 2023 [cited by applicant]
CN 100356925C · 2007 [cited by applicant]
CN 104688769B · 2015 [cited by applicant]
EP 2262535B1 · 2013 [cited by applicant]
GB 922673A · 1963 [cited by applicant]
KR 1020160012257 · 2016 [cited by applicant]
WO 9618300A2 · 1996 [cited by applicant]
WO 2009055312A1 · 2009 [cited by applicant]
WO 2012131476A1 · 2012 [cited by applicant]
WO 2017048925A1 · 2017 [cited by applicant]
Extended European Search Report in EP20852206.0, mailed Jul. 28, 2023, 11 pages. [cited by applicant]
Nien et al., “Antibacterial activity of poloxamer-modified montmorillonite clay against [cited by applicant]
Banai et al., “Influence of Extracellular Magnesium on Capillary Endothelial Cell Proliferation and Migration”, Circulation Research, vol. 67, No. 3, pp. 645-650, Sep. 1990. [cited by applicant]
Carretero, M. Isabel, “Clay minerals and their beneficial effects upon human health: A review”, Applied Clay Science, vol. 21, pp. 155-163, 2002. [cited by applicant]
Cunningham et al., “pH-Dependent Metal Ion Toxicity Influences the Antibacterial Activity of Two Natural Mineral Mixtures”, PLoS ONE, vol. 5, 10 pages, Mar. 1, 2010. [cited by applicant]
Honnegowda et al., “Role of angiogenesis and angiogenic factors in acute and chronic wound healing”, Plast. Aesthet. Res., vol. 2, Issue 5, pp. 243-249, Sep. 15, 2015. [cited by applicant]
Lansdown et al., “Zinc in wound healing: Theoretical, experimental, and clinical aspects”, Wound Rep. Reg., vol. 15, pp. 2-16, Oct. 19, 2006. [cited by applicant]
Lansdown, Alan B., “Calcium: a potential central regulator in wound healing in the skin”, Wound Repair and Regeneration, vol. 10, Issue 5, 14 pages, Nov. 4, 2002. [cited by applicant]
Lin et al., “Zinc in Wound Healing Modulation”, Nutrients, vol. 10, Issue 16, 20 pages, Dec. 24, 2017. [cited by applicant]
Morrison et al., “Mineralogical Variables that Control the Antibacterial Effectiveness of a Natural Clay Deposit”, Environ Geochem Health, vol. 36, pp. 613-631, 2014. [cited by applicant]
Sarsour et al., “MnSOD activity regulates hydroxytyrosol-induced extension of chronological lifespan”, Age, vol. 34, pp. 95-109, 2012. [cited by applicant]
Serena et al., “Nutrition in patients with chronic non-healing ulcers: a paradigm shift in wound care”, Chronic Wound Care Management and Research, vol. 5, pp. 5-9, 2018. [cited by applicant]
Williams et al., “Killer Clays! Natural antibacterial clay minerals”, Mineralogical Society Bulletin, pp. 3-8, Apr. 2004. [cited by applicant]
Gaskell et al., “Antimicrobial clay-based materials for wound care” Future Medicinal Chemistry, vol. 6, No. 6, pp. 641-655, published online Jun. 4, 2014. [cited by applicant]
International Searching Authority in connection with PCT/US2020/046109 filed Aug. 13, 2020, The International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, 11 pages,… [cited by applicant]
Viseras et al., “Clay Minerals in Skin Drug Delivery”, Clays and Clay Minerals, vol. 67, pp. 59-71, published online Apr. 5, 2019. [cited by applicant]
Afriyie-Gyawu, Evans, “Safety and Efficacy of Novasil Clay as a Dietary Supplement to Prevent Aflatoxicosis”, A Dissertation submitted to the Office of Graduate Studies of Texas A&M University, 191 pages, Dec. 2004. [cited by applicant]
Aslam et al., “Combination of Tigecycline and N-Acetylcysteine Reduces Biofilm-Embedded Bacteria on Vascular Catheters”, Antimicrobial Agents and Chemotherapy, vol. 51, No. 4, pp. 1556-1558, Apr. 2007. [cited by applicant]
Aslam et al., “Role of Antibiofilm-Antimicrobial Agents in Control of Device-Related Infections”, Int. J. Artif. Organs, vol. 34(9), pp. 752-758, Jan. 5, 2012. [cited by applicant]
Becker, Lillian C., “Safety Assessment of Glycerin as Used in Cosmetics”, Cosmetics Ingredient Review, 32 pages, Nov. 14, 2014. [cited by applicant]
Bodratti et al., “Formulation of Poloxamers for Drug Delivery”, Journal of Functional Biomaterials, vol. 9, 24 pages, Jan. 18, 2018. [cited by applicant]
Caflisch et al., “Antibacterial activity of reduced iron clay against pathogenic bacteria associated with wound infections”, International Journal of Antimicrobial Agents, vol. 52, pp. 692-696, Jul. 18, 2018. [cited by applicant]
Chen et al., “Hydroxytyrosol prevents dermal papilla cells inflammation under oxidative stress by inducing autophagy”. J. Biochem. Mol. Toxicol., 9 pages, Jun. 17, 2019. [cited by applicant]
Chowdhury et al., “Pluronic Nanotechnology for Overcoming Drug Resistance”, Nanomedicine and Nanotoxicology, Chapter 9, pp. 207-237, Aug. 19, 2017. [cited by applicant]
Cinar, Dursun, “Purification and Antimicrobial Properties of Oleuropein”, A Thesis submitted in partial fulfillment for the degree of Doctor of Philosophy at Thames Valley University, 199 pages, Apr. 2009. [cited by applicant]
Costa et al., “N-acetylcysteine-functionalized coating avoids bacterial adhesion and biofilm formation”, Scientific Reports, 13 pages, Nov. 17, 2017. [cited by applicant]
Damrau, Dr. Fredic, “The Value of Bentonite for Diarrhea”, Med. Ann. Dist. Columbia, 11 pages, Jun. 1961. [cited by applicant]
Ei-Feky et al., “Effect of Ciprofloxacin and N-acetylcysteine on Bacterial Adherence and Biofilm Formation on Ureteral Stent Surfaces”, Polish Journal of Microbiology, vol. 58, No. 3, pp. 261-267, Jul. 27, 2009. [cited by applicant]
Ghadiri et al., “Biomedical Applications of Cationic Clay Minerals”, RSC Advances, 20 pages, Mar. 9, 2015. [cited by applicant]
Ghalandari et al., “Antimicrobial effect of Hydroxytyrosol, Hydroxytyrosol Acetate and Hydroxytyrosol Oleate on [cited by applicant]
“Glycerin”, The United States Pharmacopeial Convention, Revisional Bulletin, 2 pages, May 1, 2009. [cited by applicant]
“Kelco-Vis Dg Diutan Gum, Guidelines for Proper Dissolution”, CP Kelco, A Huber Company, 2 pages, Jul. 2017. [cited by applicant]
Louie et al., “Pharmacodynamic Evaluation of the Activities of Six Parenteral Vancomycin Products Available in the United States”, Antimicrobial Agents and Chemotherapy, vol. 59, No. 1, pp. 622-632, Jan. 2015. [cited by applicant]
Moloughney et al., “Poloxamer 188 (P188) as a Membrane Resealing Reagent in Biomedical Applications”, Recent Pat Biotechnol., vol. 6(3), pp. 200-211, Dec. 2012. [cited by applicant]
Moosavi, Maryam, “Bentonite Clay as a Natural Remedy: A Brief Review”, Iran J. Public Health, vol. 46, No. 9, pp. 1176-1183, Sep. 2017. [cited by applicant]
Morrison et al., “Interactions between antibacterial clays and bacteria: Determining the reactivity and geochemistry of transition metals”, 2012 Clay Minerals Society Annual Meeting, Powerpoint, 33 pages, 2012. [cited by applicant]
Morrison, Keith D., “Unearthing the Antibacterial Activity of a Natural Clay Deposit”, A Dissertation presented in partial fulfillment of the requirements for the Degree Doctor of Philosophy, Arizona State University, 1… [cited by applicant]
Morrison et al., “Unearthing the Antibacterial Mechanism of Medicinal Clay: A Geochemical Approach to Combating Antibiotic Resistance”, Scientific Reports, 13 pages, Jan. 8, 2016. [cited by applicant]
Morrison et al., “The Anatomy of an Antibacterial Clay Deposit:k A New Economic Geology”, Economic Geology, Bulletin of the Society of Economic Geologist, vol. 112, No. 7, pp. 1551-1570, Jun. 30, 2017. [cited by applicant]
Mousa et al., “Clay nanoparticles for regenerative medicine and biomaterial design: A review of clay bioactivity”, Biomaterials, vol. 159, pp. 204-214, 2018. [cited by applicant]
Mousavi et al., “Development of Clay Nanoparticles Toward Bio and Medical Applications”, Current Topics in the Utilization of Clay in Industrial and Medical Applications, Chapter 9, pp. 167-191, Sep. 2018. [cited by applicant]
Williams et al., “Bentonite, Bandaids, and Borborygmi”, Elements (Que), vol. 5(2), pp. 99-104, Apr. 1, 2009. [cited by applicant]
Omar, Syed Haris, “Oleuropein in Olive and its Pharmacological Effects”, Scientia Pharmaceutica, 22 pages, Apr. 23, 2010. [cited by applicant]
Patel et al., “Poloxamers: A pharmaceutical excipients with therapeutic behaviors”, International Journal of PharmTech Research, vol. 1, No. 2, pp. 299-303, Apr. 2009. [cited by applicant]
“Preclinical Safety Results”, Phrixus Pharmaceuticals Inc., 2 pages, accessed on the internet on Jul. 26, 2019. [cited by applicant]
Pray, Leslie, “Antibiotic Resistance, Mutation Rates and MRSA”, Nature Education, vol. 1(1):30, 4 pages, Jul. 30, 2019. [cited by applicant]
Sircar et al., “High Performance Liquid Chromatography Analysis and Anti-Methicillin Resistant [cited by applicant]
McIntyre, Tyler, “Explanation of Shear, Temperature, and Viscosity in Petrolatum Containing Systems”, Email from Petrolia Technical Team of Sonneborn LLC to Dr. McCord, 4 pages, Jun. 30, 2017. [cited by applicant]
Sudjana et al., “Antimicrobial activity of commercial [cited by applicant]
Williams et al., “Evaluation of the medicinal use of clay minerals as antibacterial agents”, Int. Geol. Rev., vol. 52 (7/8), pp. 745-770, Jul. 1, 2010. [cited by applicant]
Williams, Lynda B., “Geomimicry: harnessing the antibacterial action of clays”, Clay Minerals, vol. 52, 24 pages, Jan. 16, 2017. [cited by applicant]
Williams et al., “What Makes a Natural Clay Antibacterial?”, Environ. Sci. Technol., vol. 45(8), pp. 3768-3773, Apr. 15, 2011. [cited by applicant]
Achenie et al., “Modelling of Drug Release from a Polymer Matrix System,” Novel Approaches in Drug Designing & Development, Aug. 7, 2017, vol. 2, No. 3, pp. 001-0010. [cited by applicant]
Bae et al., “Enhanced regenerative healing efficacy of a highly skin-permeable growth factor nanocomplex in a full-thickness excisional mouse wound model,” International Journal of Nanomedicine, 2014, vol. 9, pp. 4551-4… [cited by applicant]
Banim, “‘Trojan Horse’ Drug That Kills Cancer Without Damaging Nearby Tissue Successfully Tested,” Unilad, Jun. 1, 2021, pp. 1-6. [cited by applicant]
Behroozian, “Antimicrobial Properties of Kisameet Clay, a Natural Clay Mineral from British Columbia, Canada,” Doctoral Thesis, University of British Columbia, Aug. 2019, pp. 1-211. [cited by applicant]
Bowler et al., “Combatting wound biofilm and recalcitrance with a novel anti-biofilm Hydrofiber® wound dressing,” Wound Medicine, 2016, vol. 14, pp. 6-11. [cited by applicant]
Chen et al., “Mechanical, Rheological and Release Behaviors of a Poloxamer 407/Poloxamer 188/Carbopol 940 Thermosensitive Composite Hydrogel,” Molecules, 2013, vol. 18, pp. 12415-12425. [cited by applicant]
CPI Wurster Process, “Technologies the wurster process,” Coating Place, Inc. 2021, pp. 1-3. [cited by applicant]
Dumortier et al., “A Review of Poloxamer 407 Pharmaceutical and Pharmacological Characteristics,” Pharmaceutical Research, Nov. 11, 2006, vol. 23, pp. 2709-2728. [cited by applicant]
Ellison et al., “Controlled Release Nitrogen Fertilizers for Agriculture,” Agrium Advanced Technologies, 2012, pp. 1-31. [cited by applicant]
FDA, “Classification of Wound Dressings Combined with Drugs,” FDA Executive Summary, Sep. 20-21, 2016, pp. 1-83. [cited by applicant]
Giuliano et al., “Mucosal Applications of Poloxamer 407-Based Hydrogels: An Overview,” Pharmaceutics, Sep. 12, 2018, vol. 10, No. 159, pp. 1-26. [cited by applicant]
Hagemann, “Healing Power of Clay? Not as Off-the-Wall as You Might Think,” EOS, Dec. 12, 2018, vol. 99, pp. 1-4. [cited by applicant]
International Consensus, “Appropriate Use of Silver Dressings in Wounds,” Wounds International, 2012, pp. 1-24. [cited by applicant]
Jung et al., “Potential Anti-Inflammatory and Anti-Cancer Properties of Farnesol,” Molecules, Oct. 31, 2018, vol. 23, No. 2827, pp. 1-15. [cited by applicant]
Khan et al., “3-Hydroxytyrosol regulates biofilm growth in Cunninghamella elegans,” Fungal Biology, Nov. 2020, pp. 1-8. [cited by applicant]
Khandelwal et al., “A surfactant polymer wound dressing protects human keratinocytes from inducible necroptosis,” Nature—Scientific Reports, Feb. 23, 2021, vol. 11, No. 4357, pp. 1-15. [cited by applicant]
Kolašinac et al., “Solubility enhancement of desloratadine by solid dispersion in poloxamers,” International Journal of Pharmaceutics, 2012, vol. 436, pp. 161-170. [cited by applicant]
Kvitek et al., “Effect of Surfactants and Polymers on Stability and Antibacterial Activity of Silver Nanoparticles NPs,” J. Phys. Chem. C., 2008, vol. 112, No. 15, pp. 5825-5834. [cited by applicant]
Maisanaba et al., “Toxicological evaluation of clay minerals and derived nanocomposites: A review,” Environmental Research, 2015, vol. 138, pp. 233-254. [cited by applicant]
McDowell, “Benzethonium chloride method for proteins adapted to centrifugal analysis,” Clin Chem., Jun. 1985, vol. 31, No. 6, pp. 864-866. [cited by applicant]
Miller, “Our Geological Wonderland: Blue clay,” Our Geological Wonderland, Sep. 9, 2018, pp. 1-12. [cited by applicant]
Mishra et al., “Development and characterization of pectin/gelatin hydrogel membranes for wound dressing,” Int. J. Plast. Technol., Jun. 2011, vol. 15, No. 1, pp. 82-95. [cited by applicant]
Mogen et al., “Pluronics-Formulated Farnesol Promotes Efficient Killing and Demonstrates Novel Interactions with [cited by applicant]
Morlán et al., “Determination of poloxamer 188 and poloxamer 407 using high-performance thin-layer chromatography in pharmaceutical formulations,” Journal of Pharmaceutical and Biomedical Analysis, Mar. 13, 2008, vol. 4… [cited by applicant]
Morrison et al., “Synthetic antibacterial minerals: harnessing a natural geochemical reaction to combat antibiotic resistance,” Nature—Scientific Reports, Jan. 24, 2022, vol. 12, No. 1218, pp. 1-11. [cited by applicant]
New Directions Aromatics, “Essential Oils Containing Farnesol,” New Directions Aromatics, 1997-2021, pp. 1-2. [cited by applicant]
Nowacka et al., “Farnesol-Containing Macromolecular Systems for Antibiofilm Strategies,” Surfaces, May 21, 2020, vol. 3, pp. 197-210. [cited by applicant]
Oh et al., “The I reparation of I olyurethane Foam Combined with pH-sensitive Alginate/Bentonite Hydrogel for Wound Dressings,” Fibers and I olymers, 2011, vol. 12, No. 2, pp. 159-165. [cited by applicant]
Okano et al., “Inhibition and Induction of Quorum Sensing Using Complexes between N-Acylhomoserine Lactone and Self-assembled Polymer Micelles,” Chem. Lett., 2015, vol. 44, pp. 1544-1546. [cited by applicant]
Percival et al., “Mode of action of poloxamer-based surfactants in wound care and efficacy on biofilms,” Int. Wound J., 2018, vol. 15, pp. 749-755. [cited by applicant]
Qureshi et al., “Polysaccharide based superabsorbent hydrogels and their methods of synthesis: A review,” Carbohydrate Polymer Technologies and Applications, 2020, vol. 1, pp. 1-14. [cited by applicant]
Ramage et al., “Inhibition on Candida albicans biofilm formation using divalent cation chelators EDTA,” Mycopathologia, Oct. 2, 2007, vol. 164, No. 301, pp. 1-10. [cited by applicant]
Ricci et al., “Sustained release of lidocaine from Poloxamer 407 gels,” International Journal of Pharmaceutics, Jan. 20, 2005, vol. 288, No. 2, pp. 235-244. [cited by applicant]
Sambale et al., “Investigations of the Toxic Effect of Silver Nanoparticles on Mammalian Cell Lines,” Journal of Nanomaterials, 2015, vol. 2015, No. 136765, pp. 1-10. [cited by applicant]
Svensson et al., “Kisameet Glacial Clay: an Unexpected Source of Bacterial Diversity,” mBio, May 23, 2017, vol. 8, No. 3, pp. 1-30. [cited by applicant]
Tian et al., “Controlled drug delivery for glaucoma therapy using montmorillonite/Eudragit microspheres as an ion-exchange carrier,” International Journal of Nanomedicine, 2018, vol. 13, pp. 415-428. [cited by applicant]
Tiefenbacher, “Maltodextrin,” Advances in Food Authenticity Testing, 2016, pp. 1-8. [cited by applicant]
Treter et al., “Washing-resistant surfactant coated surface is able to inhibit pathogenic bacteria adhesion,” Applied Surface Science, 2014, vol. 303, pp. 147-154. [cited by applicant]
Wang et al., “Effects of montmorillonite clay on growth performance, nutrient digestibility, vulva size, faecal microflora, and oxidative stress in weaning gilts challenged with zearalenone,” Animal Feed Science and Tec… [cited by applicant]
Watson, “Potassium Chloride Extended-Release Capsules, USP, 8 mEq and 10 mEq”, Watson Laboratories, Inc. and Watson Pharma, Inc., Oct. 14, 2009, pp. 1-2. [cited by applicant]
Wei et al., “Phloretin inhibits biofilm formation by affecting quorum sensing under different temperature,” LWT, Sep. 2020, vol. 131, pp. 1-2. [cited by applicant]
White et al., “Water-Sorption Characteristics of Clay Minerals,” Illinois State Geological Survey, 1959, pp. 1-24. [cited by applicant]
Zarrintaj et al., “Poloxamer: A versatile tri-block copolymer for biomedical applications,” Acta Biomaterialia, 2020, vol. 110, pp. 37-67. [cited by applicant]
Park S, Murthy PK, Park S, Mohan YM, Koh WG. Preparation of silver nanoparticle-containing semi-interpenetrating network hydrogels composed of pluronic and poly (acrylamide) with antibacterial property. Journal of Indus… [cited by applicant]
Kuo et al., “Role of pH Value in Clinically Relevant Diagnosis,” Diagnostics, Feb. 16, 2020, vol. 10, No. 107, pp. 1-17. [cited by applicant]
Ratzke et al., “Modifying and reacting to the environmental pH can drive bacterial interactions,” PLoS Biology, Mar. 14, 2018, vol. 16, No. 3, pp. 1-20. [cited by applicant]
cosmeticsinfo.org, “Poloxamer 188,” The Wayback Machine, Sep. 9, 2021 [retrieved Mar. 26, 2024]. Retrieved from the Internet: <URL: https://web.archive.org/web/20210922233722/https://www.cosmeticsinfo.org/ingredient/pol… [cited by applicant]
Seema S, Datta MJ. Organoclay Pluronic F68-Montmorillonite, as a sustained release drug delivery vehicle for propranolol hydrochloride. Eur. Chem. Bull. 2014;3(6):593-604. [cited by applicant]
Bowen, P. “Particle size distribution measurement from millimeters to nanometers and from rods to platelets.” Journal of dispersion science and technology 23.5 (2002): 631-662. [cited by applicant]
Extended European Search Report in EP22888411.0, mailed Jul. 25, 2025, 8 pages. [cited by applicant]